Company Filing History:
Years Active: 2011
Title: Carsten Schultz: Innovator in Histone Deacetylase Inhibition
Introduction
Carsten Schultz is a notable inventor based in Rome, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target histone deacetylases (HDACs). His work is crucial in the fight against various diseases, including cancer and neurodegenerative disorders.
Latest Patents
Carsten Schultz holds a patent for "Heterocycle derivatives as histone deacetylase (HDAC) inhibitors." This invention relates to compounds that are effective in inhibiting HDAC, which plays a vital role in the regulation of gene expression. The compounds are useful for treating cellular proliferative diseases, including cancer, as well as neurodegenerative diseases, schizophrenia, and stroke.
Career Highlights
Carsten Schultz is associated with the Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a., where he continues to advance research in molecular biology and pharmacology. His innovative approach to drug development has positioned him as a key figure in his field.
Collaborations
He collaborates with esteemed colleagues, including Barbara Attenni and Federica Ferrigno, who contribute to the research and development of new therapeutic compounds.
Conclusion
Carsten Schultz's work in developing HDAC inhibitors represents a significant advancement in medical research. His contributions are paving the way for new treatments for serious diseases, showcasing the importance of innovation in healthcare.